| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
– Initiative aimed at improving access and outcomes for patients with recurrent pericarditis –
– American Heart Association to work with champions at 15 healthcare sites to implement initiative activities and improve care quality –
HAMILTON, Bermuda, June 17, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today announced its sponsorship of the American Heart Association's new Addressing Recurrent Pericarditis initiative, a multi-faceted effort to improve quality of care through identification, dissemination, and implementation of best practices for the diagnosis and management of recurrent pericarditis.
Posted In: KNSA
